Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

AUC: Area under the curve; COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory ... ipratropium was not recommended in asthma, except in acute severe asthma management.

A subgroup analysis of the COURSE trial also showed that treatment with tezepelumab resulted in numerical improvements in lung function as measured by forced expiratory volume (FEV1) (improvement ...

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

Connect Biopharma (CNTB) announced the online publication of results from the global Phase 2 trial of rademikibart in patients with ...